Multiple Myeloma | Exploring Clinical Investigator Perspectives on the Optimal Management of Multiple Myeloma

published 1 month ago by Dr Neil Love

Featuring perspectives from Drs Sagar Lonial and Krina K Patel, including the following topics: Existing Management Paradigm for Multiple Myeloma (MM) — Sagar Lonial, MD (0:00) Selection and sequencing of systemic therapies for patients with relapsed/refractory MM (15:14) Follow-up discussion with Dr Love and Dr Lonial (18:16) Future Directions in MM Treatment — Krina K Patel, MD, MSc (24:53) Follow-up discussion with Dr Love and Dr Patel (53:48) Case: A woman in her late 70s with multiple regimen-refractory MM receives belantamab mafodotin on a clinical trial (59:02) Case: A woman in her early 70s with relapsed/refractory MM receives B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy (1:03:43) Case: A man in his early 50s with relapsed/refractory t(11;14) MM receives venetoclax in combination with carfilzomib and dexamethasone on a compassionate-use basis (1:07:43) Induction and maintenance therapy for newly diagnosed MM (1:13:17) Management of relapsed/refractory disease (1:39:16) FDA approval of the antibody-drug conjugate belantamab mafodotin and role of BCMA-directed CAR T-cell therapies in MM (1:48:50) Future developments and novel investigational approaches in MM (2:04:46) CME information and select publications

more episodes from Research To Practice | Oncology Videos